What LENZ Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 6 |
| Sells | 0 | 2 |
| Total trades | 0 | 9 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 63,879 |
| Disposed | 0 | 10,000 |
| Net activity | +0 | +53,879 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| George Jeffrey P. | Director | Mar 27 | Open-market buy · P | +5,592 | $8.92 | +$49.9K | 5,592 |
| Schimmelpennink Evert B. | President, CEO and Secretary | Mar 27 | Open-market buy · P | +28,089 | $8.95 | +$251K | 77,289 |
| Chevallard Daniel R. | Chief Financial Officer | Mar 27 | Open-market buy · P | +7,500 | $8.57 | +$64.3K | 12,886 |
| Olsson Shawn | Chief Commercial Officer | Nov 17 | Open-market sale · S | −5,788 | $26.37 | −$153K | 4,733 |
| Olsson Shawn | Chief Commercial Officer | Nov 17 | Open-market sale · S | −4,212 | $25.74 | −$108K | 10,521 |
| Olsson Shawn | Chief Commercial Officer | Nov 17 | Exercise / conversion · M | +10,000 | $2.08 | +$20.8K | 14,733 |
| Mccollum James W | Director | Nov 07 | Open-market buy · P | +10,500 | $22.79 | +$239K | 10,500 |
| Chevallard Daniel R. | Chief Financial Officer | Nov 07 | Open-market buy · P | +2,178 | $22.76 | +$49.6K | 5,386 |
| Chevallard Daniel R. | Chief Financial Officer | Nov 07 | Open-market buy · P | +20 | $22.71 | +$454 | 3,208 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −123 | $47.01 | −$5.78K | 764,127 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −177 | $47.01 | −$8.32K | 1,050,599 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −57,502 | $46.41 | −$2.67M | 764,250 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −83,066 | $46.41 | −$3.85M | 1,050,776 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −34,405 | $45.35 | −$1.56M | 821,752 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 30 | Open-market sale · S | −49,701 | $45.35 | −$2.25M | 1,133,842 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 18 | Open-market sale · S | −132 | $43.30 | −$5.72K | 856,157 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 18 | Open-market sale · S | −268 | $43.30 | −$11.6K | 1,183,543 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 18 | Open-market sale · S | −20,148 | $43.00 | −$866K | 856,289 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 18 | Open-market sale · S | −40,907 | $43.00 | −$1.76M | 1,183,811 |
| Versant Venture Capital VI, L.p. | 10% owner | Sep 18 | Open-market sale · S | −24,370 | $41.59 | −$1.01M | 876,437 |
Loading...